We are reviewing claims of patients diagnosed with cancer after using Zantac (ranitidine).
Contact us for a case evaluation
Free Case EVALUATION
Zantac No Longer Available in U.S. Due to Cancer-Causing Contaminant
In April 2020, the U.S. Food and Drug Administration announced the agency had requested manufacturers of prescription and over-the-counter ranitidine (Zantac) medications immediately withdraw the medication from the market. As part of an ongoing investigation, public health officials determined the medication exposes consumers to unacceptable levels of the carcinogen N-Nitrosodimethylamine (NDMA).
FDA Requests All Ranitidine (Zantac) Products Pulled from Market
- Prescription and over-the-counter ranitidine products (Zantac) are no longer available in the United States
- In April 2020, the U.S. Food and Drug Administration requested manufacturers immediately withdraw all ranitidine products from the U.S. market
- In 2019, retailers including CVS, Walgreens, and Walmart pulled ranitidine products from their shelves
FDA Studies Confirm: NDMA Levels in Zantac Increase Under Normal Storage Conditions
U.S. Food and Drug administration testing and evaluation confirm that levels of the carcinogen N-Nitrosodimethylamine, (NDMA) in ranitidine medications (Zantac) increase even under ordinary storage conditions. NDMA levels increase even more significantly when the medication is exposed to higher temperatures, including during distribution and handling by consumers.
NDMA levels were also found to increase the older the products were, and the longer time had passed since manufacturing.